KR100368126B1 - Composition capable of inhibiting sebum secretion - Google Patents

Composition capable of inhibiting sebum secretion Download PDF

Info

Publication number
KR100368126B1
KR100368126B1 KR10-2000-0058768A KR20000058768A KR100368126B1 KR 100368126 B1 KR100368126 B1 KR 100368126B1 KR 20000058768 A KR20000058768 A KR 20000058768A KR 100368126 B1 KR100368126 B1 KR 100368126B1
Authority
KR
South Korea
Prior art keywords
sebum
acne
composition
secretion
herb
Prior art date
Application number
KR10-2000-0058768A
Other languages
Korean (ko)
Other versions
KR20020027947A (en
Inventor
손의동
박원석
남개원
이병곤
Original Assignee
주식회사 태평양
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 태평양 filed Critical 주식회사 태평양
Priority to KR10-2000-0058768A priority Critical patent/KR100368126B1/en
Publication of KR20020027947A publication Critical patent/KR20020027947A/en
Application granted granted Critical
Publication of KR100368126B1 publication Critical patent/KR100368126B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • A61K36/14Cupressaceae (Cypress family), e.g. juniper or cypress
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/10Washing or bathing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Insects & Arthropods (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 사상자, 백자인 및 상표초로 이루어진 군에서 선택된 1종 이상의 추출물을 함유하여 피부에서 과잉으로 분비되는 피지를 억제하므로 인하여, 여드름, 여드름에 의한 모공확대, 지루성 피부염 등의 피지 관련 질환을 예방 또는 치료할 수 있는 조성물에 관한 것이다.The present invention contains one or more extracts selected from the group consisting of casualties, white porcelain, and trademarked herb to inhibit sebum that is excessively secreted from the skin, thereby preventing sebum-related diseases such as acne, acne enlargement, pore enlargement, and seborrheic dermatitis. It relates to a composition that can be treated.

Description

피지 분비 억제용 조성물{Composition capable of inhibiting sebum secretion}Composition capable of inhibiting sebum secretion

본 발명은 사상자, 백자인 및 상표초로 이루어진 군에서 선택된 1종 이상의 추출물을 함유하여 피부에서 과잉으로 분비되는 피지를 억제할 수 있는 조성물에 관한 것이다.The present invention relates to a composition capable of suppressing sebum that is excessively secreted from the skin by containing one or more extracts selected from the group consisting of casualties, white porcelains and trademarked herb.

일반적으로 두피 및 얼굴을 포함한 피부에서 피지는 피부의 보습유지나 미생물의 침입을 막는 역할을 담당하지만, 피지가 과잉으로 분비되면, 여드름이 악화되며, 여드름에 의한 모공확대가 촉진되고, 지루성 피부염이 발생하는 등 여러 가지 질환이 유발된다.그러나, 지금까지 개발된 물질들은 그 근본적인 원인을 제거할 수 있는 물질이기보다는 여드름 등과 같은 질환 자체의 치료를 목적으로 개발된 물질이기 때문에, 그 치유효과가 미비하고, 또한 그 예방적 개념은 전무한 상황이다.In general, sebum in the skin including the scalp and face plays a role of keeping the skin moisturizing or preventing the invasion of microorganisms, but when the sebum is excessively secreted, acne worsens, promotes enlargement of pores by acne, and seborrheic dermatitis occurs. However, the substances developed so far are not substances that can eliminate the root cause, but are developed for the purpose of treating diseases such as acne. In addition, the preventive concept is absent.

이러한 피지의 과분비는 여러 원인에 의해서 발생하는데, 그 중에서도 가장 중요한 것은 피지선의 활성에 있어 피지 분비를 촉진하는데 관여하는 호르몬 가운데 하나인 디하이드로테스토스테론(dihydrotestosterone: DHT)의 양에 의해서 피지선의 세포가 활성화되어 피지가 과분비되는 것이다.The secretion of sebum is caused by a number of causes, the most important of which is the activation of cells of the sebaceous gland by the amount of dihydrotestosterone (DHT), one of the hormones involved in promoting sebaceous gland secretion. Sebum is over secreted.

즉, 피부의 피지선에서는 테스토스테론(testosterone:T)이 5-알파-리덕타제 타입 1 (5-α-reductase type 1)에 의해서 디하이드로테스토스테론으로 전환되어 세포질 내에 있는 수용체 단백질(receptor)과 결합하여 핵내로 들어가 피지선 세포를 활성화하여 분화가 촉진됨으로써 피지선내의 피지(sebum)를 과분비하여 여드름을 유발하는 것이다(J.Invest Dermatol 105:209-214 Diane etc.).That is, in the sebaceous glands of the skin, testosterone (T) is converted to dihydrotestosterone by 5-alpha-reductase type 1, which binds to receptor proteins in the cytoplasm and nucleus. By entering the inside of the sebaceous gland cells to promote differentiation, sebum (sebum) in the sebaceous glands (sebum) is to cause acne (J. Invest Dermatol 105: 209-214 Diane etc.).

따라서, 피지의 과분비의 원인을 제거하여, 피지 과분비에 의해 유발되는 지루성 피부염, 여드름 등의 질환을 치료 및 예방하고자 하였다.Therefore, the cause of sebaceous hypersecretion was removed to treat and prevent diseases such as seborrheic dermatitis and acne caused by sebaceous hypersecretion.

이에, 본 발명자들은 그 근본적 원인을 제거하여 질환을 예방 또는 치료하고자 피지의 과분비 자체를 억제할 수 있는 물질을 연구하게 되었고, 이러한 연구의 일환으로 이미 안전성이 입증되어 있는 천연물들 중에서 유효물질을 검색한 결과, 사상자, 백자인 및 상표초로 이루어진 군에서 선택된 1종 이상의 추출물이 5-알파-리덕타제의 저해효과와 지질 생합성 억제 효과가 있으므로, 과도하게 분비되는 피지를 억제할 수 있음을 발견하고 본 발명을 완성하게 되었다.Thus, the present inventors have studied a substance that can suppress sebum hypersecretion itself in order to prevent or treat the disease by removing the root cause, and search for an active substance among natural products that have already been proven safe as part of such research. As a result, one or more extracts selected from the group consisting of casualties, white porcelains, and trademarked herb have the inhibitory effect of 5-alpha-reductase and the inhibitory effect of lipid biosynthesis, and thus can be found to inhibit excessive secretion of sebum. To complete.

따라서, 본 발명의 목적은 피부에서 과잉으로 분비되는 피지를 억제하여 피지 관련 질환을 예방 또는 치료할 수 있는 조성물을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a composition capable of preventing or treating sebum-related diseases by inhibiting sebum excessively secreted from the skin.

상기한 목적을 달성하기 위하여, 본 발명에 따른 조성물은 사상자, 백자인 및 상표초로 이루어진 군에서 선택된 1종 이상의 추출물을 함유하는 것을 특징으로 한다.In order to achieve the above object, the composition according to the present invention is characterized in that it contains one or more extracts selected from the group consisting of casualty, white porcelain and trademark herb.

이하, 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.

본 발명에서 사용된 사상자, 백자인 및 상표초에 관한 일반적인 성상, 응용 및 확인 시험법은 다음과 같다.The general properties, applications, and confirmatory test methods for casualties, white porcelains and trademark candles used in the present invention are as follows.

사상자(Torilis Fructus)는 Torilis japonica Decanodolle(미나리과)의 과실로 타원형의 상현과로서 각 분과는 편평하고 길이 2~4㎜, 지름 1㎜이다. 분과의 바깥면은 회황색~회갈색으로 끝부분에 작은 돌기가 있고, 밑부분에는 가는 과병이 붙어있다. 등쪽면은 3개의 늑선이 있고 봉합면은 평탄하나 2개의 갈색 늑선이 있다. 사상자는 향기가 있고 맛은 조금 맵고 혀를 자극한다(대한약전외 한약 규격집). 남자의 음위. 습양, 부인음종, 관절통, 자궁냉증 등의 치료에 사용된다(동양학 개론).Tolis Fructus is a fruit of Torilis japonica Decanodolle (Apiaceae), an elliptical standing genus that is flat, 2-4 mm long, and 1 mm in diameter. The outer surface of the branch is grayish yellow to grayish brown with small protrusions at the end, and the lower part has a thin fruit disease. Dorsal side with 3 ribs, suture surface flat, but with 2 brown edges. Casualties are fragrant, taste is a little spicy and irritate the tongue. Man's genitals. It is used for the treatment of weaning, gynecological, arthralgia, and hypothermia (introduction to oriental science).

백자인(Thujae semen)은 측백나무(Thuja orientalis)의 종자로 난원형~긴 타원형이거나 또는 긴 원주형이고 길이 3~5㎜, 지름 2~3㎜이다. 바깥면은 엷은 황색~황백색이고, 오래된 것은 점차 변하여 황갈색이 되며 기름이 스며 나온다. 종자의 바깥면은 흔히 얇은 막질의 내종피로 싸여있고, 끝은 대개 뾰족하며, 원삼 능형으로 진한 갈색의 점이 있다. 아래쪽은 둔한 원형으로 색이 엷다. 이약의 횡단면을 현미경으로 살펴보면 백색~황백색이고 배유가 많으며 풍부한 지방질이 함유되어 있다(대한약전외 한약 규격집). 달고 평하며 독이 없고 향기롭다. 작용은 심비를 보하고 정신을 편안하게 하며 피를 돕고 땀을 멎게한다. 간장과 신장을 윤택하게 하며, 허리가 무겁고 아픈 것을 치료한다. 백자인은 양심안신(養心安神), 윤장통편(潤腸通便)의 효능이 있다(동양학 개론).Thujae semen is a seed of Thuja orientalis, oval to long oval or long cylindrical, 3 to 5 mm long and 2 to 3 mm in diameter. The outer surface is pale yellow to yellowish white, and the old one gradually changes to yellowish brown color and oil leaks out. The outer surface of the seed is often wrapped with a thin membranous inner epidermis, the tip is usually pointed, and has a dark brown spot with a round triangular ridge. The lower part is a dull round and light in color. Microscopic examination of the cross-section of this drug is white to yellowish white, rich in oil, and rich in fat. Sweet, flat, nonpoisonous, and fragrant. The action is to see the heart, relax the mind, help the blood and sweat. The liver and kidneys are moisturized and the lower back is healed and healed. Baekjain has the efficacy of conscience of the god Anyang (안 心 安神) and Yun Jang Tongpyeon (潤腸 通便).

상표초(Mantidid ootheca)는 당랑소, 단표초라기도 하며, 사마귀과의 Mantidae의 알이 들어 있는 벌레집을 찐 것이다. 이 생약은 원주형~반원형으로 여러 개의 막으로 된 엷은 층이 쌓여 배열되어 있고, 길이 24~45㎜, 너비 2~3㎝, 두께 15~20㎜이다. 바깥면은 엷은 갈색~황갈색이고, 위쪽면은 액간 융기되어 있으며, 아래면은 평탄하거나 식물의 줄기에 붙었던 자국이 있다. 성질은 달고 짜며 평하고 독이 없다. 양위 유정, 조설, 유노실금, 월경 폐지증에 사용한다.(대한약전외 한약 규격집, 동약학 개론;서경 출판사).Mandidid ootheca, also known as dung beetle and single herb, is a boiled worm house containing mantidae eggs from the mantis family. This herb is columnar to semicircular, with thin layers of several membranes arranged, stacked 24 to 45 mm long, 2 to 3 cm wide, and 15 to 20 mm thick. The outer side is light brown to yellowish brown, the upper side is liquid intercalated, and the lower side is flat or has marks on the stem of the plant. The nature is sweet, salty, flat and nonpoisonous. It is used for elder oil well, establishment, uno incontinence, and abolition of menstruation.

본 발명은 상기한 효능이 있는 사상자, 백자인 및 상표초의 추출물을 유효성분으로 하여 피부에서의 피지의 분비를 억제할 수 있는 조성물을 제공한다.The present invention provides a composition capable of inhibiting the secretion of sebum in the skin by using the above-mentioned extracts of filamentous, white porcelain and trademark herb as active ingredients.

본 발명에서 사용된 사상자, 백자인 및 상표초의 추출물은 생약재로부터 침출, 전출 또는 침출액을 다시 일부 또는 전부 농축하고, 혹은 다시 그 농축물을 건조하여 제조한 침제, 전제, 정기, 유동 엑기스 등(이하 추출 엑기스라 함)과, 생약재중에 함유되고 주 효과를 발휘하는 화학 물질 그 자체도 포함한다.Extracts of filamentous, white porcelain and trademark herb used in the present invention are concentrated, leached, leached or leached from the medicinal herb again or partially concentrated, or dried again to produce a leaching, premises, regular, flow extract (hereinafter extraction) Extracts) and the chemicals contained in the herb and which have a major effect.

본 발명의 생약재 추출물의 추출방법은 생약재를 저급 알코올, 헥산, 에틸아세테이트 또는 디에틸에테르로 추출하거나, 무수 또는 함수 에탄올 또는 메탄올 추출물 중 헥산, 에틸아세테이트, 물층의 분획을 추출한 것이다. 좀더 상세히 설명하면 다음과 같다. 시판되고 있는 사상자, 백자인 및 상표초를 구입하여 잘게 분쇄하고, 분쇄물 건조중량에 대하여 에탄올, 메탄올 등의 유기용매를 단독으로 3~5배의 용량으로 가한 뒤, 냉각콘덴서가 장치된 추출기에서 50~100℃의 온도로 1~10시간 동안 가열하여 추출하거나, 생약재를 상기 용매에 0~40℃의 온도에서 1~30일간 침적하여 유효성분을 추출할 수 있다. 이렇게 추출한 3종의 생약 추출물은 감압 증발기를 사용하여 완전히 건조시켜 건조분말로 만들어 사용하였다.Extraction method of the herbal medicine extract of the present invention is to extract the herbal medicine with lower alcohol, hexane, ethyl acetate or diethyl ether, or extract the fraction of hexane, ethyl acetate, water layer in anhydrous or hydrous ethanol or methanol extract. More detailed description is as follows. Commercially available casualties, white porcelains and trademarked candles are pulverized, and the organic solvents such as ethanol and methanol alone are added to a capacity of 3 to 5 times with respect to the dry weight of the pulverized product, and then 50 minutes in an extractor equipped with a cooling capacitor. Extract by heating for 1 to 10 hours at a temperature of ~ 100 ℃, or by dipping the herbal medicine at the temperature of 0 to 40 ℃ in the solvent for 1 to 30 days to extract the active ingredient. The three herbal extracts thus extracted were completely dried using a reduced pressure evaporator and used as dry powders.

이들을 사용하여 피지의 과다 분비의 원인인 활성남성호르몬의 생성을 억제하기 위하여 그 생성에 직접적으로 관여하는 효소인 5-알파-리덕타아제의 활성 억제력, 지질합성(Lipogenesis) 억제력 및 토끼를 이용한 면포감소 시험을 실시한 결과, 이들 생약재 추출물은 5-알파-리덕타아제의 활성 및 지질의 합성을 억제할 수 있고, 면포를 감소시킬 수 있다는 것을 발견하였다.In order to suppress the production of active male hormone which is the cause of excessive secretion of sebum, the activity of inhibiting the activity of 5-alpha-reductase, an enzyme directly involved in the production, the inhibition of Lipogenesis and the cotton wool using rabbit As a result of the reduction test, these herbal extracts were found to be able to inhibit the activity of 5-alpha-reductase and the synthesis of lipids and to reduce the scrim.

따라서, 이러한 효능을 갖는 사상자, 백자인 및 상표초로 이루어진 군에서 선택된 1종 이상의 추출물을 함유하는 조성물은 피지의 과다 분비가 억제되므로, 피지의 과다 분비로 인하여 발생하는 질환, 예를 들면, 여드름, 지루성 피부염, 지루성 피부염에 의한 비듬, 여드름에 의해 모공확대 등이 예방 또는 치료될 수 있다.Therefore, the composition containing one or more extracts selected from the group consisting of casualties, white porcelain and trademark herb having such efficacy suppresses the excessive secretion of sebum, so diseases caused by the excessive secretion of sebum, for example, acne, seborrheic Dermatitis, dandruff caused by seborrheic dermatitis, pore enlargement by acne, etc. can be prevented or treated.

본 발명의 조성물은 조성물 총 중량에 대하여, 사상자, 백자인 및 상표초로 이루어진 군에서 선택된 1종 이상의 추출물을 0.001~10중량%의 양으로 함유하는 것이 바람직하다. 이는 0.001중량% 미만으로 사용하는 경우 피지분비 억제 효과가 없으며, 10중량%를 초과하여 사용하는 경우에는 피부에 자극을 유발할 수 있기 때문이다.The composition of the present invention preferably contains one or more extracts selected from the group consisting of casualty, white porcelain, and trademark herb in an amount of 0.001 to 10% by weight, based on the total weight of the composition. This is because when used less than 0.001% by weight, there is no sebum secretion inhibitory effect, when used in excess of 10% by weight may cause irritation to the skin.

본 발명의 조성물은 피부에 적용할 수 있는 통상적인 제형으로 제형화될 수 있으며, 예를 들면 화장수, 크림, 로션, 스킨로션, 팩, 파운데이션 등과 같은 화장품 뿐만 아니라 액상비누, 고형비누, 세안 폼(foam)과 같은 인체세정제 등으로 제형화될 수 있다. 이들 각 제형은 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있으며, 이들 성분의 종류와 양은 당업자에 의해 용이하게 선정될 수 있다.The composition of the present invention may be formulated in a conventional formulation that can be applied to the skin, for example, liquid soap, solid soap, facial foam (as well as cosmetics such as lotion, cream, lotion, skin lotion, pack, foundation, etc.) It may be formulated with a human cleanser such as foam). Each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulations, and the types and amounts of these components can be readily selected by those skilled in the art.

이하 실시예 및 시험예를 들어 본 발명을 상세히 설명하지만, 본 발명이 이들예로만 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples and Test Examples, but the present invention is not limited to these examples.

[실시예 1] 사상자 추출물의 제조Example 1 Preparation of Casualty Extract

사상자 100g에 70% 메탄올을 150㎖를 가하고 냉각 콘텐서가 달려있는 추출기에서 2시간 가량 끓여서 추출한 후 여과하여 찌꺼기를 제거하고 사상자 추출액을 만들었다. 이 추출물을 냉각콘덴서가 달린 증류장치를 이용하여 60℃에서 감압 농축하여 건조잔량을 2g 얻었다.150 g of 70% methanol was added to 100 g of the casualties, boiled for about 2 hours in an extractor equipped with a cooling condenser, and then filtered to remove debris to prepare a casualty extract. The extract was concentrated under reduced pressure at 60 ° C. using a distillation apparatus equipped with a cooling capacitor to obtain 2 g of a dry residue.

[실시예 2] 백자인 추출물 제조Example 2 Preparation of White Porcelain Extract

백자인 100g에 비극성 용매인 헥산 200㎖를 가하고 냉각 콘텐서가 달려있는 추출기에서 2시간 가량 끓여서 추출한 후 여과하여 찌꺼기를 제거하고 백자인 추출액을 만들었다. 이 추출물을 냉각콘덴서가 달린 증류장치를 이용하여 60℃에서 감압 농축하여 건조잔량을 5g 얻었다.200 g of hexane, a non-polar solvent, was added to 100 g of white porcelain, boiled for about 2 hours in an extractor equipped with a cooling condenser, and then filtered to remove residue and white porcelain extract was prepared. The extract was concentrated under reduced pressure at 60 ° C. using a distillation apparatus equipped with a cooling capacitor to obtain 5 g of a dry residue.

[실시예 3] 상표초 추출물의 제조Example 3 Preparation of Extract

상표초 100g에 에틸아세테이트 200㎖를 가하고 냉각콘텐서가 달려있는 추출기에서 2시간 가량 끓여서 추출한 후 여과하여 찌꺼기를 제거하고 상표초 추출액을 만들었다. 이 추출물을 냉각콘덴서가 달린 증류장치를 이용하여 60℃에서 감압 농축하여 건조잔량을 8g 얻었다.200 ml of ethyl acetate was added to 100 g of trademark vinegar, boiled for 2 hours in an extractor equipped with a cooling capacitor, extracted, filtered to remove the residue, and the extract was extracted. The extract was concentrated under reduced pressure at 60 ° C. using a distillation apparatus equipped with a cooling capacitor to obtain 8 g of dry residue.

[시험예 1] 5-알파-리덕타제 활성 억제 효과[Test Example 1] 5-alpha-reductase activity inhibitory effect

성숙한 Sprogue-Dawley 웅성랫트(생후 7-8주)를 디에틸에테르로 치사시킨 후, 복부 전립선을 떼내어 결합조직을 제거하고, 완충액(0.32M sucrose, 0.1mM dithiothreitol, 20mM sodium acetate)을 첨가하여 잘게 자른 다음, 분쇄기로 현탁화하였다. 현탁액은 원심 분리하여 상층액을 취해 5-알파-리덕타제를 부분정제하여, 이 효소의 활성도 억제 실험을 수행하였다.Mature Sprogue-Dawley male rats (7-8 weeks old) were killed with diethyl ether, the abdominal prostate was removed, the connective tissue was removed, and buffered (0.32 M sucrose, 0.1 mM dithiothreitol, 20 mM sodium acetate) was added. Finely chopped and then suspended in a grinder. The suspension was centrifuged to obtain the supernatant, partially purified with 5-alpha-reductase, and the activity inhibition experiment of this enzyme was performed.

위에서 얻은 상층액의 일부를 취하여 0.2M 일염기산과 0.2M 이염기산이 들어 있는 완충액에 넣은 후, 동위원소인3H가 붙어있는 기질(테스토스테론)과 함께 반응시켜 생성물인 다이하이드로테스토스테론의 생성량을 측정하였다.Taking a portion of the supernatant obtained above was placed in a buffer containing 0.2M monobasic acid and 0.2M dibasic acid, is reacted with isotope substrate (testosterone) marked with 3 H measure the production of dihydro testosterone in product It was.

반응용액은 1mM 디티오트레이톨, 40mM 나트륨 포스페이트(pH 6.5), 50μM NADPH, [1,2,6,7-3H] 테스토스테론/테스토스테론(2.2×109몰), 효소 현탁액(0.8㎎) 을 넣어 총 부피가 565㎕가 되게 하였다.The reaction solution was added 1 mM dithiothreitol, 40 mM sodium phosphate (pH 6.5), 50 μM NADPH, [1,2,6,7-3H] testosterone / testosterone (2.2 × 10 9 mol), and enzyme suspension (0.8 mg). The total volume was brought to 565 μl.

시료는 10% 에탄올에 0.1%가 되도록 녹인 후, 위의 반응용액에 5.65㎕ 첨가하여 최종농도가 0.001%가 되도록 하였다. 대조 실험으로는 같은 부피의 용매, 양성 대조 실험으로는 리보플라빈을 이용하였다.The sample was dissolved in 10% ethanol to 0.1%, and then 5.65 μl was added to the reaction solution so that the final concentration was 0.001%. The same volume of solvent was used as a control experiment and riboflavin was used as a positive control experiment.

반응은 효소 현탁액을 부가함과 함께 시작하여 37℃에서 30분간 진행시킨후, 1㎖의 에틸아세테이트를 가하여 추출하였으며, 100㎕의 에틸아세테이트상을 실리카 플라스틱 시트 카이젤겔 60 에프 254(Silica plastic sheet kieselgel 60 F254)상에서, 전개용매계는 아세테이트-사이클로 헥산(1:1)으로 하여 전개하였다.The reaction was started with addition of the enzyme suspension and proceeded at 37 ° C. for 30 minutes, followed by extraction by adding 1 ml of ethyl acetate. 100 μl of ethyl acetate was extracted from silica plastic sheet kieselgel 60 254 (Silica plastic sheet kieselgel). 60 F254), the developing solvent system was developed with acetate-cyclohexane (1: 1).

플라스틱 시트를 공기 건조한 후, 동위원소의 양을 측정하기 위해 바스 시스템을 사용하였는데, 건조된 플라스틱 시트와 엑스레이 필름을 함께 바스 카셋트에 넣어 1주일 후에 필름에 남아있는 테스토스테론과 디하이드로테스토스테론의 동위원소양을 측정하였다.After air drying the plastic sheet, the bath system was used to measure the isotope amount. The isotopic amount of testosterone and dihydrotestosterone remaining in the film after one week by placing the dried plastic sheet and the x-ray film together in the bath cassette. Was measured.

각각의 저해율에 대한 결과는 표 1에 나타내었다. 한편, 하기 표 1에서 시료에서 각 실시예들의 혼합비율은 1:1이다.The results for each inhibition rate are shown in Table 1. On the other hand, the mixing ratio of each embodiment in the sample in Table 1 is 1: 1.

시료sample T(dpm)T (dpm) DHT(dpm)DHT (dpm) 전환율(%)% Conversion 저해율(%)% Inhibition 실시예 1Example 1 77307730 23552355 23.423.4 4444 실시예 2Example 2 93309330 27212721 22.622.6 4646 실시예 3Example 3 68786878 21002100 23.423.4 4444 실시예 1+실시예 2Example 1+ Example 2 68506850 12201220 15.115.1 6464 실시예 1+실시예 3Example 1+ Example 3 73507350 14001400 16.016.0 6262 실시예 2+실시예 3Example 2+ Example 3 72557255 11171117 13.313.3 6868 실시예 1+실시예 2+실시예 3Example 1 + Example 2 + Example 3 94129412 11331133 10.710.7 74.574.5 대조군Control 75307530 55465546 4242 -- 양성 대조군Positive control 63006300 25332533 28.728.7 31.631.6 (1) T : 테스토스테론 영역에서 나타난3H 레디오 엑티버티(2) DHT: 디하이드로테스토스테론 영역에서 나타난3H 레디오 엑티버티(3) 전환율: DHT 영역의 레디오 엑티버티/토탈 레디오 엑티버티(4) 저해율: 100×(대조군의 전환율- 시료의 전환율)/대조군의 전환율(1) T: 3 H radioactivity in the testosterone region (2) DHT: 3 H radio activity (3) conversion in the dihydrotestosterone region (3) Conversion rate: Radio activity / total radio activity in the DHT region (4) inhibition rate : 100 × (conversion rate-conversion rate of sample) / conversion rate of control

상기 표 1로부터, 사상자, 백자인 및 상표초로 이루어진 군에서 선택된 1종 이상의 추출물은 5-알파 리덕테이즈 억제 효과가 있음을 알 수 있다.From Table 1, it can be seen that one or more extracts selected from the group consisting of filamentous, white porcelain and trademark herb has an effect of inhibiting 5-alpha reductase.

[시험예 2] 지질합성(lipogenesis) 억제효과Test Example 2 Lipogenesis Synthesis Inhibitory Effect

지질 합성에 필요한 탄소 원소의 소비(uptake) 정도를 정량하여 지질합성 저해 정도를 평가하는 방법으로 피지선에서의 지질합성 정도를 평가하였다.The degree of lipid synthesis in sebaceous glands was evaluated by quantifying the uptake of carbon elements required for lipid synthesis to evaluate the degree of inhibition of lipid synthesis.

즉, 피지선이 많은 햄스터 귀 조직을 생검(biopsy)하여 C14이 라벨된 배지에서 6시간 동안 방사능 측정기로 대조군과 시료군을 비교 정량하여 저해 정도를 평가하였다. 시료군으로는 햄스터 오른쪽 귀 조직을 이용 배지에 시료 용액 0.01%를 가하여 사용하였고, 대조군으로는 햄스터 왼쪽 귀 조직을 이용 배지에 생리 식염수 0.01%를 가하여 사용하였다. 그 결과는 표 2와 같다.That is, the degree of inhibition was evaluated by biopsy of hamster ear tissues with many sebaceous glands and comparing the control group and the sample group with a radiometer for 6 hours in a C 14 labeled medium. As a sample group, 0.01% of the sample solution was added to the medium using hamster right ear tissue, and 0.01% of physiological saline was added to the medium using the hamster left ear tissue as a control group. The results are shown in Table 2.

한편, 표 2에서 저해율은 하기 수학식 1에 따라 계산한 것이고, 그 값은 4 마리의 햄스터에 대한 평균값이다.On the other hand, the inhibition rate in Table 2 is calculated according to the following equation 1, the value is the average value for the four hamsters.

시료sample 저해율(%)% Inhibition 실시예 1Example 1 5555 실시예 2Example 2 4343 실시예 3Example 3 4747 실시예 1+실시예 2Example 1+ Example 2 5858 실시예 1+실시예 3Example 1+ Example 3 6666 실시예 2+실시예 3Example 2+ Example 3 7575 양성 대조군(레티노인산)Positive control (retinoic acid) 5252

상기 표 2로부터, 사상자, 백자인 및 상표초 추출물이 지질 생합성 억제 효과가 있음을 알 수 있고, 각각에 있어서보다는 혼합물로 사용시 효과가 증가됨을 알 수 있다.From Table 2, it can be seen that the filamentous, white porcelain and trademark herb extracts have an inhibitory effect on lipid biosynthesis, and the effect is increased when used in a mixture rather than in each case.

이러한 결과들은 남성 호르몬 억제 시험인 시험예 1의 결과와 비슷한 양상을보였다.These results were similar to those of Test Example 1, a testosterone suppression test.

[시험예 3] 면포 감소 효과Test Example 3 Cotton Cloth Reduction Effect

면포감소효과를 확인하기 위하여 본 발명에 사용된 생약재인 사상자, 백자인 및 상표초 추출물의 건조분말(실시예 1~3)을 1,3-부틸렌글리콜에 용해시켜 1% 용액이 되도록 한 후, 토끼 임상실험용 시험물질로 사용하였다.In order to confirm the effect of reducing the cotton cloth dry powder (Examples 1 to 3) of the herbal extract, white porcelain and trademark herb extracts used in the present invention were dissolved in 1,3-butylene glycol to 1% solution, It was used as a test material for rabbit clinical trials.

흰 토끼의 귀에 면포 유발 물질인 50% 올레인산/파라핀오일 0.2㎖를 오전에 도포하여 면봉으로 문질러 준다. 하루 두 번 오전(50% 올레인산/파라핀오일), 오후(물질)에 도포하며 총 실험 기간인 한달 동안 도포한다. 면포는 약 10일 전후부터 발생되는데, 물질을 0.2㎖씩 오후에 도포해준 결과 2주후부터는 점차적으로 면포의 수 및 크기가 감소하였다.The rabbit's ears are applied with 0.2ml of 50% oleic acid / paraffin oil, a cotton-causing substance, in the morning and rubbed with a cotton swab. It is applied twice a day in the morning (50% oleic acid / paraffin oil), in the afternoon (material) and for a month during the total experiment. Cotton cloth was generated from about 10 days, and the number and size of the cotton cloth gradually decreased from 2 weeks after applying 0.2ml of the material in the afternoon.

각 조직을 생검하여 각질을 벗겨낸 후, 면포 크기를 현미경 하에서 측정하였다. 그 결과를 표 3에 나타내었다.After each tissue was biopsied and exfoliated, the scrim size was measured under a microscope. The results are shown in Table 3.

시료sample 평균 명포 크기 측정(0.1㎜) N=3Average name cloth size measurement (0.1mm) N = 3 미처리Untreated 1.781.78 올레인산(OA)Oleic acid (OA) 3.53.5 OA+실시예 1OA + Example 1 3.03.0 OA+실시예 2OA + Example 2 2.52.5 OA+실시예 3OA + Example 3 2.82.8 OA+실시예 1+실시예 2OA + Example 1+ Example 2 2.52.5 OA+실시예 1+실시예 3OA + Example 1+ Example 3 2.32.3 OA+실시예 2+실시예 3OA + Example 2+ Example 3 2.42.4 OA+실시예 1+실시예 2+실시예 3OA + Example 1+ Example 2+ Example 3 2.12.1

표 3으로부터, 본 발명에 따른 생약재로 처리한 토끼의 면포가 현저히 감소되었다는 것을 알 수 있다. 즉, 생약재에 의해 피지감소가 나타나고, 결과적으로 피부 과각질화를 감소시켜 면포가 감소되었음을 추정할 수 있다.From Table 3, it can be seen that the cotton cloth of the rabbit treated with the herbal medicine according to the present invention was significantly reduced. That is, it can be estimated that sebum reduction is caused by the herbal medicine, and as a result, skin hyperkeratosis is reduced, thereby reducing the cotton cloth.

상기 시험예 1~3으로부터, 본 발명의 조성물에 함유되는 사상자, 백자인 및 상표초 추출물은 피지 분비 억제에 효과가 있는 물질임을 알 수 있다.From Test Examples 1 to 3, it can be seen that the filamentous, white porcelain and trademark herb extracts contained in the composition of the present invention are substances effective in suppressing sebum secretion.

[시험예 4] 피지분비 억제 및 여드름 완화 효과[Test Example 4] sebum secretion suppression and acne alleviation effect

여드름으로 고민하는 남녀 10명과 별도로 얼굴에 피지분비가 많다고 느끼는 남녀 9명을 선정하여 아래의 제형예 1에 따른 처방으로 4주간 여드름 부위와 얼굴의 피지 분비가 많은 곳을 매일 바르게 하였다.In addition to 10 men and women who are suffering from acne, 9 men and women who feel sebum secretion on the face were selected and prescribed according to the formulation example 1 below for 4 weeks for acne and facial sebum secretion.

효과의 판정은 시험에 참가한 본인이 느끼는 정도에 따라 점수화하였고, 피지분비 억제는 피지량 측정기를 사용하여 측정하였다. 피지분비 억제 효과에 대한 결과는 표 4에 나타내었고, 여드름 완화효과는 표 5에 나타내었다.Judgment of the effect was scored according to the degree felt by the person who participated in the test, sebum secretion inhibition was measured using a sebum measuring device. The results of the sebum secretion inhibitory effect is shown in Table 4, the acne relief effect is shown in Table 5.

[제형예 1] 영양 화장수Formulation Example 1 Nutritional Lotion

성분ingredient 함량(중량%)Content (% by weight) 사상조+백자인+상표초Sasangjo + white porcelain + trademark 1.001.00 밀납Beeswax 4.004.00 폴리솔베이트Polysorbate 1.501.50 솔비탄세스퀴올레이트Sorbitan sesquioleate 0.700.70 유동파라핀Liquid paraffin 5.005.00 카프릴릭/카프릭트리글리세라이드Caprylic / Capric Triglycerides 5.005.00 글리세린glycerin 3.003.00 부틸렌글리콜Butylene glycol 3.003.00 프로필렌글리콜Propylene glycol 3.003.00 카르복시비닐폴리머Carboxy Vinyl Polymer 0.100.10 트리에탄올아민Triethanolamine 0.200.20 방부제antiseptic 적량Quantity 색소Pigment 적량Quantity 향료Spices 적량Quantity 정제수Purified water to 100to 100

피지분비 억제 효과Sebum secretion inhibitory effect 시험자Tester 시험전피지량(㎍/㎠h)Pre-test skin level (㎍ / ㎠h) 시험 2주경과 후After 2 weeks of exam 시험 4주 경과 후4 weeks after the exam 1One 7777 6565 6363 22 5555 3838 4343 33 3535 4343 4545 44 8888 7171 6262 55 7171 6565 5555 66 2323 3333 3838 77 4848 4343 4444 88 6565 4040 4646 99 7979 6666 6161

여드름 완화효과Acne Relief 시험자Tester 시험전 상태Pre-test state 시험 2주경과 후After 2 weeks of exam 시험 4주 경과 후4 weeks after the exam 1One 1One -- ++ 22 33 ++++ ++++ 33 22 ++ ++++ 44 1One ++ ++ 55 22 -- ++ 66 33 -- ++++ 77 22 ++++ ++++++ 88 1One ++ ++++ 99 22 ++ ++ 1010 22 ++ ++++ * 시험전 상태: 1-여드름 조금 있음2-여드름 약간 있음3-여드름 심함* 효과 판정; -: 효과 거의 없음+: 약간의 효과 있음++: 많이 줄어듬+++: 완전히 치유됨* Pre-test: 1-acne slightly 2-acne slightly 3-acne * effect determination; -: Almost no effect +: Slight effect ++: Much less +++: Completely healed

상기 표 4 및 5의 결과로부터, 본 발명에 따른 조성물은 피지를 억제할 수 있고, 따라서 여드름을 완화시킬 수 있음을 알 수 있다.From the results of Tables 4 and 5, it can be seen that the composition according to the present invention can inhibit sebum, and thus alleviate acne.

이하. 본 발명의 조성물의 제형을 예를 들지만, 본 발명이 이들 제형예로만 한정되는 것은 아니다.Below. Although the formulation of the composition of the present invention is exemplified, the present invention is not limited only to these formulation examples.

[제형예 2] 크림Formulation Example 2 Cream

원료명Raw material name 중량%weight% 사상자유동 파라핀세토스테아릴알코올밀납메틸폴리실록산친유형모노스테아린산 스테아레이트스테아린산소리비탄세스퀴올레이트모노스테아린산폴리옥시에칠렌소르비탄(E.O=20)메틸파라벤프로필파라벤향료에틸렌디아민테트라초산디나트륨글리세린프로필렌글리콜트리에탄올아민이미다졸리디닐우레아정제수Filamentous free flowing paraffin cetostearyl alcohol beeswax methyl polysiloxane lipophilic monostearic acid stearate stearic acid sorbitan sesquioleate monostearic acid polyoxyethylene sorbitan (EO = 20) methyl paraben propyl paraben perfume ethylene diamine tetra acetate disodium glycerol propylene glycol triethanol amine Imidazolidinyl urea 0.115.02.03.00.52.02.00.81.01.20.20.10.20.025.05.00.20.3to 1000.115.02.03.00.52.02.00.81.01.20.20.10.20.025.05.00.20.3to 100

[제형예 3] 로션[Formulation Example 3] Lotion

원료명Raw material name 중량%weight% 백자인멀티왁스스테릭엑시드유동파라핀디하이데그왁스비왁스 17니콜 MGS-B아라셀 #165글리세린메틸파라벤프로필파라벤리퀴드파라벤트윈 #60카보머정제수White porcelain Multi wax Sterile EX liquid paraffin dihydride wax be wax 17 Nicol MGS-B alasel # 165 glycerin methyl paraben propyl paraben liquid paraben twin # 60 carbomer tablet water 0.13.60.55.00.80.051.90.77.00.120.035.00.50.12to 1000.13.60.55.00.80.051.90.77.00.120.035.00.50.12to 100

[제형예 4] 유연 화장수Formulation Example 4 Flexible Lotion

원료명Raw material name 중량%weight% 상표초생귀나린메틸폴리실록산메틸파라벤향료폴리옥시에틸렌노릴페닐에텔폴리옥시에틸렌경화피마자유초산토코페롤에탄올글리세린에틸렌디아민테트라초산디나트륨프로필렌글리콜트리에탄올아민정제수Super paraffin methyl methyl siloxane methyl paraben flavoring polyoxyethylene noryl phenyl ether polyoxyethylene hardening castor oil tocopherol ethanol glycerol ethylene diamine tetra acetate disodium propylene glycol triethanol amine 0.10.050.50.20.20.30.50.110.08.00.023.00.2to 1000.10.050.50.20.20.30.50.110.08.00.023.00.2to 100

[제형예 5] 팩[Formulation Example 5] Pack

원료명Raw material name 중량%weight% 백자인+상표초구연산폴리비닐알코올셀룰로오스검글리세린폴리옥시에틸렌글리콜 400옥틸도데실에텔(E.O.=16)에탄올방부제색소향정제수White porcelain + trademark polyvinyl citrate polyvinyl alcohol cellulose gum glycerin polyoxyethylene glycol 400 octyldodecyl ether (E.O. = 16) ethanol preservative pigment flavor water 0.11.014.00.11.01.00.40.6적량적량적량to 1000.11.014.00.11.01.00.40.6appropriate quantityto 100

[제형예 6] 팩[Formulation Example 6] Pack

원료명Raw material name 중량%weight% 사상자+상표초구연산폴리비닐알코올셀룰로오스검글리세린폴리옥시에틸렌글리콜 400옥틸도데실에텔(E.O.=16)에탄올방부제색소향정제수Casualty + trademark Citric acid Polyvinyl alcohol Cellulose gum Glycerin Polyoxyethylene glycol 400 Octyl dodecyl ether (E.O. = 16) Ethanol Preservative Pigment 0.11.014.00.11.01.00.40.6적량적량적량to 1000.11.014.00.11.01.00.40.6appropriate quantityto 100

[제형예 7] 고형 비누Formulation Example 7 Solid Soap

원료명Raw material name 중량%weight% 사상자+백자인+상표초이산화티탄폴리에틸렌글리콜글리세린에틸렌디아민테트라아세트산나트륨색소비누향화장비누베이스(수분 13%, 중량부)Casualty + White porcelain + Trademark Titanium dioxide Polyethylene glycol Glycerine Ethylenediamine Sodium sodium acetate Soap flavoring equipment Nubase (moisture 13%, parts by weight) 0.10.20.80.50.051.0적량적량to 1000.10.20.80.50.051.0 Suitable for 100

이상에서 설명한 바와 같이, 사상자, 백자인 및 상표초로부터 선택된 1종 이상의 추출물을 함유한 피지 분비 억제용 조성물은 사람에게 사용했을 때 매우 안전하면서도 피지분비를 감소시키는 효과가 우수하므로, 여드름, 지루성 피부염, 여드름에 의한 모공확대 등과 같은 피지 관련질환의 예방 또는 치료제에 유효농도로 사용할 수 있다.As described above, sebum secretion inhibiting composition containing one or more extracts selected from casualties, white porcelain and trademark herb is very safe when used in humans and has an excellent effect of reducing sebum secretion, thus acne, seborrheic dermatitis, It can be used in effective concentrations for the prevention or treatment of sebum-related diseases such as enlarged pores caused by acne.

Claims (3)

사상자, 백자인 및 상표초로 이루어진 군에서 선택된 1종 이상의 추출물을 함유하는 것을 특징으로 하는 피지 분비 억제용 조성물.Sebum secretion, white porcelain and trademark herb secretion sebum secretion composition characterized in that it contains one or more extracts selected from the group consisting of. 제 1항에 있어서, 상기 사상자, 백자인 및 상표초로 이루어진 군에서 선택된 1종 이상의 추출물은 조성물 총 중량에 대하여 0.001~10중량%의 양으로 함유됨을 특징으로 하는 조성물.The composition of claim 1, wherein the at least one extract selected from the group consisting of casualties, white porcelains, and trademarked herbs is contained in an amount of 0.001 to 10% by weight, based on the total weight of the composition. 제 1항 또는 제 2항에 있어서, 상기 조성물이 여드름 또는 여드름에 의한 모공확대의 예방 또는 치료제인 조성물.The composition according to claim 1 or 2, wherein the composition is an agent for preventing or treating pore enlargement caused by acne or acne.
KR10-2000-0058768A 2000-10-06 2000-10-06 Composition capable of inhibiting sebum secretion KR100368126B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2000-0058768A KR100368126B1 (en) 2000-10-06 2000-10-06 Composition capable of inhibiting sebum secretion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2000-0058768A KR100368126B1 (en) 2000-10-06 2000-10-06 Composition capable of inhibiting sebum secretion

Publications (2)

Publication Number Publication Date
KR20020027947A KR20020027947A (en) 2002-04-15
KR100368126B1 true KR100368126B1 (en) 2003-01-24

Family

ID=19692159

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-0058768A KR100368126B1 (en) 2000-10-06 2000-10-06 Composition capable of inhibiting sebum secretion

Country Status (1)

Country Link
KR (1) KR100368126B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100444102B1 (en) * 2001-12-21 2004-08-11 주식회사 태평양 Cosmetic composition for trichogenousness containing Thujae semen extract
KR100441726B1 (en) * 2001-12-21 2004-07-27 주식회사 태평양 Cosmetic composition for trichogenousness containing Mantidid ootheca extract
KR100596316B1 (en) * 2004-11-03 2006-07-03 주식회사 케이티앤지 Composition of health functional food to support skin beauty and antiaging
KR101629453B1 (en) * 2015-12-07 2016-06-10 주식회사 사임당화장품 Composition containing Mantidid ootheca extract for skin volume augmentation or improving wrinkle and elasticity

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03220129A (en) * 1990-01-22 1991-09-27 Shiseido Co Ltd Sebum suppressant
KR930021192A (en) * 1992-04-11 1993-11-22 이형주 Herbal lotion containing herbal medicine and its manufacturing method
KR19980028315A (en) * 1996-10-22 1998-07-15 유서희 Chinese herbal mud massage composition
KR20000049439A (en) * 2000-03-17 2000-08-05 서숙자 The raw material of oriental herb mask for pimples.
KR20000056433A (en) * 1999-02-22 2000-09-15 김수남 gel-solvent for massage and manufacturing method there of

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03220129A (en) * 1990-01-22 1991-09-27 Shiseido Co Ltd Sebum suppressant
KR930021192A (en) * 1992-04-11 1993-11-22 이형주 Herbal lotion containing herbal medicine and its manufacturing method
KR19980028315A (en) * 1996-10-22 1998-07-15 유서희 Chinese herbal mud massage composition
KR20000056433A (en) * 1999-02-22 2000-09-15 김수남 gel-solvent for massage and manufacturing method there of
KR20000049439A (en) * 2000-03-17 2000-08-05 서숙자 The raw material of oriental herb mask for pimples.

Also Published As

Publication number Publication date
KR20020027947A (en) 2002-04-15

Similar Documents

Publication Publication Date Title
JP2001163794A (en) Promoter for production of hyaluronic acid and preparation for external use for skin
KR20130015339A (en) Cream composition for treating acne
KR20080079802A (en) Composition of skin external application for moisturizing comprising scrophularia buergeriana miq. extract
JP2006257056A (en) Estrogenic agent and composition for skin care preparation for external use
JP2006137690A (en) Skin external preparation and hyaluronic acid production accelerator
JP2001158728A (en) Agent for promoting production of hyaluronic acid and skin preparation for external use
KR102443283B1 (en) Cosmetic composition with excellent skin barrier using skin microbiome
KR100482694B1 (en) Liposome base for trichogenousness, Cosmetic composition for trichogenousness containing the same, and Method for improving absorptance of natural ingredients for trichogenousness using the same
KR100754748B1 (en) Compositiion for Inhibiting 5?-Reductase Activity and Cosmetic Composition for Inhibiting Secretion of Sebum containing Extract of Ulmus davidiana as Active Ingredient
KR100368126B1 (en) Composition capable of inhibiting sebum secretion
KR101587447B1 (en) Cosmetic composition with BL-S extract by the supercritical extraction with the effect of skin sebum control, skin barrier intention, skin moisture control and skin protection
JP2008239494A (en) External preparation for skin
KR20090032583A (en) ALPINIA OFFICINARUM EXTRACT FOR INHIBITING OF 5alpha;-REDUCTASE ACTIVITY AND COSMETIC COMPOSITION FOR INHIBITING OF SEBUM SECRETION OR IMPROVING OF ACNES
KR20080111249A (en) A cosmetic composing chia seed extract
KR100858627B1 (en) Cosmetic Composition for Inhibiting Secretion of Sebum containing Extract of Fritillaria verticillata as Active Ingredient
JP4100805B2 (en) Cosmetics
JP3998085B2 (en) Hyaluronic acid amount increase accelerator
KR100702329B1 (en) Compositiion for Inhibiting 5?-Reductase Activity and Cosmetic Composition for Inhibiting Secretion of Sebum containing Extract of Chelidonium majus as Active Ingredient
KR20200074287A (en) Composition for Improving Skin Condition or for Quasi-Drugs, Comprising Plant Extracts
KR102465138B1 (en) Cosmetic composition comprising mixed fermented extract of medicinal plants (Phytoestrogenbiom) as an active ingredient
KR20050081550A (en) Hypoallergenic cosmetics formulation containing botanical extracts for acne skin
KR102333132B1 (en) Cosmetic Composition containing Frangipani Oil or Fermented Frangipani Oil
KR20180088051A (en) Compositions for decreasing sebum and improving acne comprising extracts of Pinus densiflora leaf, Artemisia annua and Citrus junos fruit
KR20130033228A (en) Composition of cosmetic and treating skin disease
KR100310613B1 (en) Euphorbia Lathyris extract inhibiting the activity of 5a-reductase, and the cosmetic or skincare-pharmaceutical composition thereof for suppressing pimple or sebum

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121221

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20131231

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20141231

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20151231

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20171222

Year of fee payment: 16

FPAY Annual fee payment

Payment date: 20190102

Year of fee payment: 17